BH.IMMUN&BIO | ZYDUS LIFESCIENCES | BH.IMMUN&BIO/ ZYDUS LIFESCIENCES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -8.0 | 32.3 | - | View Chart |
P/BV | x | 1.6 | 5.4 | 28.9% | View Chart |
Dividend Yield | % | 0.0 | 0.6 | - |
BH.IMMUN&BIO ZYDUS LIFESCIENCES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
ZYDUS LIFESCIENCES Mar-23 |
BH.IMMUN&BIO/ ZYDUS LIFESCIENCES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 495 | 10.5% | |
Low | Rs | 21 | 319 | 6.4% | |
Sales per share (Unadj.) | Rs | 10.3 | 170.3 | 6.1% | |
Earnings per share (Unadj.) | Rs | -3.9 | 19.8 | -19.5% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 26.9 | -14.1% | |
Dividends per share (Unadj.) | Rs | 0 | 6.00 | 0.0% | |
Avg Dividend yield | % | 0 | 1.5 | 0.0% | |
Book value per share (Unadj.) | Rs | 20.4 | 173.0 | 11.8% | |
Shares outstanding (eoy) | m | 43.18 | 1,012.20 | 4.3% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 2.4 | 146.3% | |
Avg P/E ratio | x | -9.4 | 20.6 | -45.6% | |
P/CF ratio (eoy) | x | -9.5 | 15.1 | -62.8% | |
Price / Book Value ratio | x | 1.8 | 2.4 | 75.2% | |
Dividend payout | % | 0 | 30.3 | -0.0% | |
Avg Mkt Cap | Rs m | 1,561 | 412,144 | 0.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 24,564 | 0.6% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 172,374 | 0.3% | |
Other income | Rs m | 11 | 4,746 | 0.2% | |
Total revenues | Rs m | 457 | 177,120 | 0.3% | |
Gross profit | Rs m | -161 | 29,677 | -0.5% | |
Depreciation | Rs m | 2 | 7,227 | 0.0% | |
Interest | Rs m | 71 | 1,299 | 5.4% | |
Profit before tax | Rs m | -223 | 25,897 | -0.9% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 5,878 | -1.0% | |
Profit after tax | Rs m | -166 | 20,019 | -0.8% | |
Gross profit margin | % | -36.0 | 17.2 | -209.2% | |
Effective tax rate | % | 25.3 | 22.7 | 111.4% | |
Net profit margin | % | -37.3 | 11.6 | -321.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 100,082 | 0.4% | |
Current liabilities | Rs m | 940 | 55,267 | 1.7% | |
Net working cap to sales | % | -130.6 | 26.0 | -502.2% | |
Current ratio | x | 0.4 | 1.8 | 21.0% | |
Inventory Days | Days | 85 | 50 | 169.9% | |
Debtors Days | Days | 1,135 | 94 | 1,214.0% | |
Net fixed assets | Rs m | 1,262 | 144,776 | 0.9% | |
Share capital | Rs m | 432 | 1,012 | 42.7% | |
"Free" reserves | Rs m | 450 | 174,146 | 0.3% | |
Net worth | Rs m | 882 | 175,158 | 0.5% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 1,620 | 244,940 | 0.7% | |
Interest coverage | x | -2.2 | 20.9 | -10.3% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.3 | 0.7 | 39.1% | |
Return on assets | % | -5.9 | 8.7 | -67.9% | |
Return on equity | % | -18.9 | 11.4 | -165.0% | |
Return on capital | % | -17.2 | 15.5 | -111.0% | |
Exports to sales | % | 0 | 39.2 | 0.0% | |
Imports to sales | % | 14.5 | 11.9 | 121.3% | |
Exports (fob) | Rs m | NA | 67,577 | 0.0% | |
Imports (cif) | Rs m | 65 | 20,544 | 0.3% | |
Fx inflow | Rs m | 0 | 67,577 | 0.0% | |
Fx outflow | Rs m | 65 | 20,544 | 0.3% | |
Net fx | Rs m | -65 | 47,033 | -0.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 26,888 | 0.4% | |
From Investments | Rs m | 5 | 11,712 | 0.0% | |
From Financial Activity | Rs m | -147 | -44,004 | 0.3% | |
Net Cashflow | Rs m | -34 | -5,338 | 0.6% |
Indian Promoters | % | 59.3 | 75.0 | 79.0% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 18.4 | - | |
FIIs | % | 0.0 | 5.7 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 25.0 | 162.9% | |
Shareholders | 35,313 | 294,324 | 12.0% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | Cadila Healthcare | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.69% | -0.59% | 0.45% |
1-Month | 6.17% | -6.90% | 2.55% |
1-Year | 31.70% | 83.54% | 56.14% |
3-Year CAGR | -9.09% | 18.56% | 15.22% |
5-Year CAGR | 32.05% | 23.65% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the Cadila Healthcare share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of Cadila Healthcare the stake stands at 75.0%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of Cadila Healthcare.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
Cadila Healthcare paid Rs 6.0, and its dividend payout ratio stood at 30.3%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of Cadila Healthcare.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.